rate ≥ 70 bpm. Outcomes were the SHIFT and SIGNIFY primary composite end points and their components. Results: Of 6,505 patients in SHIFT, 2,220 (34%) reported angina at randomization. Ivabradine numerically, but not significantly, reduced the SIGNIFY primary composite end point by 8, 11 and 11% in the SHIFT angina subgroup, nonangina subgroup and overall population, respectively. Ivabradine also reduced the SHIFT primary composite end point in all 3 subgroups. Conclusions: In SHIFT, ivabradine showed consistent reduction of cardiovascular outcomes in patients with CHF; similar results were seen in the subgroup of SHIFT patients with angina.
2] . Pharmacologically reducing the heart rate improves outcomes in patients with systolic CHF, demonstrated by trials with β-blockers [3, 4] and, most recently, with ivabradine, in the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine Trial (SHIFT) [5] .
A relatively high resting heart rate also is directly associated with mortality and myocardial infarction in patients with chronic stable coronary artery disease (CAD) [6, 7] . However, in 2 large, randomized trials of ivabradine in patients with CAD, the Morbidity-Mortality Evaluation of the I f Inhibitor Ivabradine in Patients with Coronary Disease and Left Ventricular Dysfunction (BEAU-TIFUL) and the Study Assessing the Morbidity-Mortality Benefits of the I f Inhibitor Ivabradine in Patients with Coronary Artery Disease (SIGNIFY), ivabradine did not alter cardiac outcomes in patients with CAD with or without left-ventricular (LV) dysfunction [8, 9] . However, a prespecified subgroup analysis of SIGNIFY suggested that patients with CAD and angina had worse outcomes with ivabradine than with placebo [8] .
These contrasting results raise concerns that ivabradine may be associated with reduced efficacy or worsened cardiovascular outcomes in patients with CHF who have CAD, particularly those with angina [10] . To resolve this issue, we conducted a post hoc analysis to determine the outcomes of the patients in SHIFT who reported angina at enrollment, and compared these results with those of the overall SHIFT population and with those who did not report angina. We also assessed the SIGNIFY outcomes in these SHIFT-based subgroups.
Methods

Patients
In SHIFT, the enrolled adults had stable, symptomatic CHF, LV ejection fraction (LVEF) ≤ 35% and were in sinus rhythm with a resting heart rate ≥ 70 bpm. Full eligibility criteria have been described previously [5] . Evaluable patients from SHIFT were divided into subgroups based on the presence or absence of angina as reported by the investigator at study enrollment. The angina subgroup included all patients with a history of angina (reported as angina pectoris, microvascular angina, postinfarction angina, Prinzmetal angina, etc.) and who answered 'Yes' to the question, 'Is the disease still present?' at enrollment. The SHIFT nonangina subgroup included all other patients in the overall SHIFT population.
Clinical Outcomes
The ivabradine and placebo groups from SHIFT were compared in the overall randomized set, the angina subgroup and the nonangina subgroup. Outcomes were the primary composite end points of SHIFT and SIGNIFY, as well as their individual components [5, 8] . For SHIFT [5] , these components included cardiovascular death or first hospitalization for worsening heart failure; for SIGNIFY [8] , they included cardiovascular death or the first nonfatal myocardial infarction. Adverse events were tabulated by randomized treatment group and angina and nonangina subgroups.
Statistical Analysis
The treatment effect was estimated using an adjusted Cox proportional hazards model with β-blocker intake at randomization as a covariate, as described in previous SHIFT publications; p values for interaction between randomized treatment and subgroup status were also provided by the addition of treatment by subgroup interaction to the model [5] . The safety analysis set included all patients who received at least 1 dose of ivabradine.
Results
Patients
Of the 6,505 patients randomized in SHIFT, 2,220 (34%) reported angina at enrollment and they comprised the angina subgroup. The remaining 4,285 patients (66%) formed the nonangina subgroup. Demographic and disease characteristics are summarized in table 1 . Briefly, patients with angina at baseline tended to be slightly older, and more of them had higher blood pressure, severe heart failure and used β-blockers than those without angina. Within each subgroup, there were no significant differences between those who received ivabradine and those who received placebo.
Clinical Outcomes
Placebo-corrected average change in heart rate at 28 days for patients treated with ivabradine was -10.9 bpm (95% CI − 11.4 to − 10.4) for the overall SHIFT population [5] and -10.8 bpm (95% CI − 11.7 to − 10.0) and -11.0 bpm (95% CI − 11.6 to − 10.3) for the angina and nonangina subgroups, respectively.
Results for the SHIFT primary composite end point (cardiovascular death or hospital admission for worsening heart failure) were similar for those with and without angina and the overall population ( fig. 1 ). In the SHIFT angina subgroup, there were 15% fewer events in the ivabradine arm than in the placebo arm, but this did not reach statistical significance (HR 0.85; 95% CI 0.73-1.00; p = 0.055). There was a 20% reduction of events in the nonangina subgroup (HR 0.80; 95% CI 0.71-0.90; p < 0.0001), and an 18% reduction in the overall SHIFT population (HR 0.82; 95% CI 0.75-0.90; p < 0.0001). The effects of ivabradine on the components of the SHIFT primary composite end point were also similar in the overall SHIFT population, SHIFT angina subgroup and SHIFT nonangina subgroup.
The rates of ontreatment adverse events and adverse events of interest in the angina and nonangina subgroups were consistent with those in the overall SHIFT population, with bradycardia and phosphenes/blurred vision being reported more frequently with ivabradine than with placebo ( table 2 ) .
When the SIGNIFY end points were applied to the SHIFT population, the results were similar in the 3 SHIFT-based groups for the primary composite end point of cardiovascular death and nonfatal myocardial infarction as well as for its components ( fig. 2 ) . A test of interaction between randomized treatment and the pres- Values are expressed as n (%) or mean ± SD. BMI = Body mass index; DBP = diastolic blood pressure; eGFR = estimated glomerular filtration rate; NYHA = New York Heart Association; SBP = systolic blood pressure. Values express n (%). AV = Atrioventricular. a Includes symptomatic and asymptomatic bradycardia. 
Discussion
The results of this analysis suggest that in patients with systolic CHF (and specifically in a population defined as in SHIFT), the risk of cardiovascular death or hospitalization for worsening heart failure is consistently reduced by slowing of the heart rate with ivabradine among patients with or without angina. Resting heart rate is a known and modifiable risk factor in heart failure when patients are in sinus rhythm. Thus, as heart rate increases, adverse outcomes increase, and when heart rate is pharmacologically slowed, adverse outcomes diminish [11] . However, in patients with cardiovascular disease without LV dysfunction or CHF, increasing heart rate is a risk marker, indicating that other processes (e.g. diabetes and smoking) are influencing the development of myocardial infarction or cardiovascular death [12] ; modification of the marker does not appear to modify the disease [8, 9] . Given the lack of efficacy of ivabradine in patients with angina and without CHF in SIGNIFY, the evaluation of the efficacy and safety of ivabradine in other patient groups with angina was needed. Because patients with systolic CHF often have underlying CAD and may also experience angina, it is possible that this subgroup of patients with CHF may have a different response to ivabradine than those with CHF without underlying angina. Therefore, this post hoc analysis evaluated the effects of slowing heart rate with ivabradine in the subgroup of SHIFT patients with CHF and angina.
The worsening outcomes seen in the SIGNIFY population with angina (no CHF and no overlap in LVEF with the SHIFT population) were not observed in the SHIFT population. For the SHIFT and SIGNIFY primary composite end points and their components, the results in the SHIFT angina subgroup were directionally consistent with both the overall SHIFT population and the SHIFT nonangina subgroup. Specifically, ivabradine numerically (but not significantly) reduced the SIGNIFY primary composite end point of cardiovascular death or nonfatal myocardial infarction versus placebo for both SHIFT subgroups and significantly in the overall SHIFT population. Similar results were observed for nonfatal myocardial infarction, with the exception of the nonangina subgroup, in which a nonsignificant increase of 2% was observed for ivabradine versus placebo. However, in the general context of a directionally consistent but statistically nonsignificant result for myocardial infarction in the overall group, the small directionally opposite finding in a subgroup probably is best attributed to chance alone.
Patients in the nonangina subgroup who received ivabradine achieved a statistically significant reduction in the risk of the SHIFT primary composite end point (cardiovascular death or hospitalization for worsening heart failure) compared with placebo. Patients in the angina subgroup tended to benefit from ivabradine, although the treatment difference was not statistically significant versus placebo (p = 0.055). The lack of significance may relate to the limited power to detect differences in the relatively small angina subgroup, which was half the size of the nonangina cohort. These results are consistent with those observed from previous post hoc analyses of ivabradine use in patients with stable CAD and LV systolic dysfunction. BEAUTIFUL evaluated ivabradine up to 7.5 mg twice daily in 10,917 patients with CAD and LVEF <40% [9] . In that study, there was a significantly higher rate of cardiovascular death and hospital admissions for heart failure in patients with a heart rate ≥ 70 bpm at baseline compared with those with a heart rate <70 bpm at baseline [13] . Furthermore, ivabradine did not significantly affect the rate of the primary composite end point (cardiovascular death or hospitalization for myocardial infarction or new-onset/worsening heart failure) or of cardiovascular death alone. However, it did lead to a reduction in the secondary end points (hospitalization for myocardial infarction and coronary revascularization) among patients in BEAUTIFUL whose heart rate was ≥ 70 bpm at randomization (a prespecified subanalysis) [9] . Conversely, in the 1,507 patients from BEAUTIFUL whose limiting symptom at baseline was angina, ivabradine was associated with a 24% reduction in the primary composite end point (HR 0.76; 95% CI 0.58-1.00; p = 0.05) [14] . In addition, a 12% reduction in cardiovascular death (HR 0.88; 95% CI 0.62-1.27; p = 0.51) and a 16% reduction in hospitalization for worsening heart failure (HR 0.84; 95% CI 0.53-1.33; p = 0.99) were seen, although these reductions did not reach statistical significance [14] . Our results and those observed in BEAUTI-FUL suggest that the reduction in hospitalization for worsening heart failure observed in SHIFT is generalizable to the subset of patients with CHF and angina.
It is not clear why the SHIFT results differ from those of SIGNIFY. Several possible explanations might be considered. First, of course, the phenotypes of the study populations differed markedly in SHIFT and SIGNIFY. As noted previously, there was no overlap in the baseline LVEF between the 2 studies; CHF was present in all SHIFT patients but not in any SIGNIFY patients. Drug doses were allowed to be higher in SIGNIFY than in SHIFT, and the background therapies for CHF required in SHIFT were not required and were often absent in SIG-NIFY, being used only if indicated for some non-CHF comorbidity. Indeed, in an overarching review of the experience in SHIFT, BEAUTIFUL and SIGNIFY, it was concluded that the efficacy of slowing the heart rate with ivabradine in preventing angina does not translate into the mitigation of pathologic alterations in the coronary arteries or to the sudden or gradual progression of these lesions that underlie clinical sequelae in CAD. However, slowing the heart rate has a profound effect on myocardial biology, leading to the functional improvement and relief of CHF and its sequelae [12] .
Although this last conclusion is empirically correct, the fundamental basis for the different effects of heart rate on the arteries and myocardium is not clear and is the subject of speculation. The processes underlying these differences may include a differential depletion in myocardial norepinephrine levels in early-stage CHF that occurs before the onset of symptomatic heart failure [15] ; this may preferentially affect the myocardium instead of the coronary arteries. Another possible explanation is that slowing the heart rate with ivabradine has a differential effect on arterial wave form reflections/arterial stiffness in patients with CHF [16] compared to in those without CHF, e.g. the patients with chronic CAD in SIGNIFY. Prior studies have suggested that β-blockers can increase pulse wave reflections/arterial stiffness, thereby negating the blood-pressure-lowering effects on cardiovascular mortality and specifically precluding the reduction of central aortic blood pressure, which may be attributable in part to heart rate reduction [17] . However, a cross-over study specifically examining ivabradine versus β-blockers showed no effect of ivabradine on central aortic pressure [18] . Therefore, central pulse wave reflections and blood pressure effects are unlikely to explain the results of SIGNIFY or to negate the results of SHIFT in patients with CAD with or without angina.
Finally, in comparing outcomes between SHIFT and SIGNIFY, the relative use of β-blocker background therapy in each trial specifically must be considered. In SIG-NIFY, 83% of patients in each group (placebo or ivabradine) were receiving a β-blocker at randomization (62% were receiving evidence-based agents for systolic heart failure, i.e. drugs allowed in SHIFT) [8] compared with 89 and 90% of patients in each group in SHIFT [5] , a relatively modest difference; in the SHIFT angina cohort, the use of β-blockers was 93% in the ivabradine group and 92% in the placebo group ( table 1 ) . In addition, in SIGNIFY, of those receiving ivabradine, 1% began with a β-blocker during the study versus 2% of those randomized to receive placebo, while 3 and 2%, respectively, stopped β-blocker treatment during the trial [8] . Given the use of multiple β-blockers in SIGNIFY in addition to those recommended for heart failure, a direct comparison between the trials is not possible. However, on average, the doses of the evidence-based β-blockers employed in SIGNIFY were virtually indistinguishable from the doses achieved in SHIFT. In SHIFT, 46% of the ivabradine group and 44% of the placebo group received carvedilol, with an average daily dose of 25 mg daily for each group [5] . In SIGNIFY, 10% of each group received carvedilol, with average daily doses of 24 and 25 mg in the ivabradine and placebo groups, respectively [8] . Most importantly, perhaps, the baseline heart rate was 77 bpm in both groups in SIGNIFY and 80 bpm in both groups in SHIFT, and fell (placebo subtracted) 10 bpm in the ivabradine group in SIGNIFY and 11 bpm (placebo subtracted) in SHIFT. Thus, the differences in heart rates, heart rate responses and β-blocker usage in the 2 studies, while potentially contributory, are unlikely to explain the apparent benefits of ivabradine in the patients with angina in SHIFT.
Several limitations must be considered in interpreting the results of this study. This was a post hoc analysis; therefore, it was designed to generate rather than to test a hypothesis. Also, angina was reported by SHIFT investigators with no protocol-specified definition. Consequently, the potential exists for bias in reporting or determining symptoms. Finally, the power to discriminate among differences in group results was relatively limited, and several of the nominal differences did not reach statistical significance, thus limiting the strength of the conclusions.
Nonetheless, this post hoc analysis demonstrates that ivabradine treatment is acceptably safe in patients with moderate-to-severe CHF and, specifically, among those who also have angina pectoris. The analysis also suggests that outcome benefits of ivabradine among such patients are similar to those seen in individuals without angina and all patients with CHF.
